- Home
- FACT vs CRGX Comparison
FACT vs CRGX Comparison
Compare FACT & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FACT
- CRGX
- Stock Information
- Founded
- FACT 2024
- CRGX 2021
- Country
- FACT United States
- CRGX United States
- Employees
- FACT N/A
- CRGX N/A
- Industry
- FACT
- CRGX
- Sector
- FACT
- CRGX
- Exchange
- FACT NYSE
- CRGX Nasdaq
- Market Cap
- FACT 246.1M
- CRGX 213.5M
- IPO Year
- FACT 2024
- CRGX 2023
- Fundamental
- Price
- FACT $10.11
- CRGX $4.07
- Analyst Decision
- FACT
- CRGX Hold
- Analyst Count
- FACT 0
- CRGX 7
- Target Price
- FACT N/A
- CRGX $4.67
- AVG Volume (30 Days)
- FACT 29.8K
- CRGX 747.0K
- Earning Date
- FACT 01-01-0001
- CRGX 05-16-2025
- Dividend Yield
- FACT N/A
- CRGX N/A
- EPS Growth
- FACT N/A
- CRGX N/A
- EPS
- FACT N/A
- CRGX N/A
- Revenue
- FACT N/A
- CRGX N/A
- Revenue This Year
- FACT N/A
- CRGX $58.18
- Revenue Next Year
- FACT N/A
- CRGX N/A
- P/E Ratio
- FACT N/A
- CRGX N/A
- Revenue Growth
- FACT N/A
- CRGX N/A
- 52 Week Low
- FACT $9.85
- CRGX $3.00
- 52 Week High
- FACT $10.32
- CRGX $25.45
- Technical
- Relative Strength Index (RSI)
- FACT N/A
- CRGX 39.56
- Support Level
- FACT N/A
- CRGX $3.97
- Resistance Level
- FACT N/A
- CRGX $4.32
- Average True Range (ATR)
- FACT 0.00
- CRGX 0.20
- MACD
- FACT 0.00
- CRGX -0.05
- Stochastic Oscillator
- FACT 0.00
- CRGX 12.50
About FACT FACT II ACQUISITION CORP
FACT II Acquisition Corp is a blank check company.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.